LSE:0QDU

NeuroVive Pharmaceutical AB Year End Report January - December 2019

STOCKHOLM, Feb. 19, 2020 /PRNewswire/ -- Important events in 2019 KL1333            * NeuroVive enrolls first subject in its European KL1333 phase Ia/b clinical study            * NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study            * NeuroVive compl...

2020-02-19 16:08 5212

NeuroVive Announces Settlement in Dispute With CicloMulsion AG

LUND, Sweden, Dec. 16, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that it has fully and finally settled the dispute with CicloMulsion AG regarding certain pharmaceutical technology. In 2004, NeuroVive entered into a License Agreement wi...

2019-12-16 18:33 5235

NeuroVive Pharmaceutical AB Interim Report January - September 2019

STOCKHOLM, Nov. 20, 2019 /PRNewswire/ -- Important events July - September * NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study * NeuroSTAT receives Fast Track designation from the US Food and Drug Administration. Financial information third quarter (July-Septem...

2019-11-20 16:38 2785

NeuroVive Pharmaceutical AB Interim Report January - June 2019

STOCKHOLM, Aug. 21, 2019 /PRNewswire/ -- Important events April - June * The US Food and Drug Administration, FDA, approves NeuroVive's IND (Investigational New Drug) application, enabling clinical studies in the US with the company's drug candidate NeuroSTAT. * The Supreme Court delivers it...

2019-08-21 15:24 7050

NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDA

LUND, Sweden, May 10, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the US Food and Drug Administration, FDA, has approved NeuroVive's IND (Investigational New Drug) application, enabling clinical studies in the US with the company's ...

2019-05-10 15:05 4687

NeuroVive Pharmaceutical AB Publishes 2018 Annual Report

LUND, Sweden, 25 March 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the English version of the Annual report for 2018 is now available on the company's website  www.neurovive.com

2019-03-25 17:58 6131

NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial Disorders

LUND, Sweden, Nov. 15, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that the company has been awardedSEK 1.5 million as a first tranche of total SEK 5 million in funding from Vinnova,Sweden's innovation agency, and the Swelife call, for i...

2018-11-15 19:37 647

NeuroVive Reports First NeuroSTAT Clinical Efficacy Signal in TBI

LUND, Sweden, Oct. 4, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced the successful completion of biomarker analyses of samples from its clinical study in severe traumatic brain injury patients (the CHIC study) using the company's investigat...

2018-10-04 15:43 630

NeuroVive Reports Promising Progress in its Clinical Project for Genetic Mitochondrial Diseases, KL1333

LUND, Sweden, Dec. 11, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm today announced that the phase I clinical study in Korea within the companies' joint project KL1333, an investigational treatment for genetic mitochondrial disorders, inc...

2017-12-11 18:56 1466

Amended Number of Shares and Votes in NeuroVive Pharmaceutical AB (publ)

LUND, Sweden, Nov. 30, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced an increase of the number of shares and votes in NeuroVive of 1,760,000 as a result of a directed share issue in NeuroVive Pharmaceuti...

2017-11-30 19:51 795

NeuroVive's Genetic Mitochondrial Disease Program NVP015 Reaches Significant Milestone

LUND, Sweden, Nov. 30, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that molecules in its NVP015 program have demonstrated positive effects in experimental models of genetic mitochondrial disease and th...

2017-11-30 16:26 750

NeuroVive Presents TBI Clinical Study Results at Nordic Neurotrauma Conference

LUND, Sweden, Nov. 15, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company will present data from its clinical phase IIa study on traumatic brain injury (TBI), Copenhagen Head Injury Ciclosporin Study (CHIC), at the Nordic Neurot...

2017-11-15 16:48 714

NeuroVive Signs Collaboration Agreement With University of Florida for TBI Biomarker Development

LUND, Sweden, Oct. 31, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company has signed a collaboration agreement withKevin K.W. Wang, Ph.D., of the University of Florida to conduct biomarker research for NeuroVive's traumatic brai...

2017-10-31 16:32 682

NeuroVive and Lund University Collaboration Receives Grant for Liver Cancer Research

LUND, Sweden, Oct. 18, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that NeuroVive andRamin Massoumi at Lund University have been granted 2.5 MSEK from the Swedish Foundation for Strategic Research (SFF...

2017-10-18 15:05 1007

NeuroVive's Collaborator, the Children's Hospital of Philadelphia Awarded NIH Grant to Study NVP015 Against Chemical Threats

LUND, Sweden, Oct. 6, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (NASDAQ Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that its research collaboration partner the Children's Hospital ofPhiladelphia (CHOP) has received a two-year grant, #1R21NS103826-01f ...

2017-10-06 05:44 888

NeuroVive Receives Research Grant From Vinnova for Development of the NVP015 Genetic Mitochondrial Disease Project

LUND, Sweden, June 1, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company receives close to 1 million SEK in a research grant from Swedish innovation agency, Vinnova, for developing a new treatment for genetic mitochondrial diseas...

2017-06-01 19:52 2439

NeuroVive Pharmaceutical AB Interim Report January - March 2017

STOCKHOLM, May 18, 2017 /PRNewswire/ -- Broadened project portfolio Business operations Significant events January-March 2017 * Strong inhibitory effects demonstrated in human hepatocellular carcinoma cells and in an experimental model of liver cancer with the Company's new generation of s...

2017-05-18 15:18 1696

NeuroVive in-licenses a Genetic Mitochondrial Disease Clinical Stage Project From Yungjin Pharm

LUND, Sweden and SEOUL, South Korea, May 2, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today jointly announced that they have entered into a global licensing agreement on Yungjin P...

2017-05-02 11:51 1708

NeuroVive Presents Preclinical Findings of NV556 in NASH Showing Confirmatory Anti-fibrotic Effects

LUND, Sweden, April 20, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) ("NeuroVive")today announced positive preclinical results demonstrating anti-fibrotic effects with NV556, the company's preclinical compound for non-alcoholic steatohepatitis (NASH), in ...

2017-04-20 15:05 1742